ArticleCellular oncology (Dordrecht, Netherlands)2025

PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma.

Ruolan Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.